ID

13744

Descrizione

A Study of AS1411 Combined With Cytarabine in the Treatment of Patients With Primary Refractory or Relapsed Acute Myeloid Leukemia; ODM derived from: https://clinicaltrials.gov/show/NCT01034410

collegamento

https://clinicaltrials.gov/show/NCT01034410

Keywords

versioni (1)
  1. 02/03/16 02/03/16 -
Titolare del copyright

CC BY-NC 3.0

Caricato su

2 marzo 2016

DOI

Per favore, per richiedere un accesso.

Licenza

Creative Commons BY-NC 3.0
Commenti del modello :

Puoi commentare il modello dati qui. Tramite i fumetti nei gruppi di articoli e articoli è possibile aggiungere commenti a quelli in modo specifico.

Torna ai commenti del modello
Commenti del gruppo di articoli per :

Commenti dell'articolo per :

Per scaricare i modelli di dati devi essere registrato. Per favore accesso o registrati GRATIS.

Eligibility Acute Myeloid Leukemia NCT01034410

Inglese

Eligibility Acute Myeloid Leukemia NCT01034410

1 moduli  
Inclusion Criteria
Descrizione

Inclusion Criteria

Alias
UMLS CUI
C1512693
diagnosis of aml as defined by the world health organization (who) classification (vardiman 2009)
Descrizione

diagnosis of aml as defined by the world health organization (who) classification (vardiman 2009)

Tipo di dati

boolean

Alias
UMLS CUI [1]
C0023467
primary refractory aml (defined as a failure to achieve a cr or cri after therapy with curative intent) or aml in first relapse
Descrizione

primary refractory aml (defined as a failure to achieve a cr or cri after therapy with curative intent) or aml in first relapse

Tipo di dati

boolean

Alias
UMLS CUI [1,1]
C0023467
UMLS CUI [1,2]
C0205269
ecog performance status 0, 1 or 2
Descrizione

ecog performance status 0, 1 or 2

Tipo di dati

boolean

Alias
UMLS CUI [1]
C1520224
age > 18 and < 70 years
Descrizione

age > 18 and < 70 years

Tipo di dati

boolean

Alias
UMLS CUI [1]
C0001779
for patients presenting with primary refractory aml, > 20% blasts on baseline bone marrow assessment
Descrizione

for patients presenting with primary refractory aml, > 20% blasts on baseline bone marrow assessment

Tipo di dati

boolean

Alias
UMLS CUI [1,1]
C0023467
UMLS CUI [1,2]
C0205269
UMLS CUI [2]
C1982687
for patients presenting with relapsed aml, > 5% blasts on baseline bone marrow assessment
Descrizione

for patients presenting with relapsed aml, > 5% blasts on baseline bone marrow assessment

Tipo di dati

boolean

Alias
UMLS CUI [1]
C1982687
UMLS CUI [2,1]
C0023467
UMLS CUI [2,2]
C0277556
Exclusion Criteria
Descrizione

Exclusion Criteria

Alias
UMLS CUI
C0680251
an initial diagnosis of acute promyelocytic leukemia (as defined by french-american-british criteria (bennett 1976))
Descrizione

an initial diagnosis of acute promyelocytic leukemia (as defined by french-american-british criteria (bennett 1976))

Tipo di dati

boolean

Alias
UMLS CUI [1]
C0023487
secondary aml, defined as aml evolving from antecedent hematological disorder or prior exposure to leukemogenic therapy or agent
Descrizione

secondary aml, defined as aml evolving from antecedent hematological disorder or prior exposure to leukemogenic therapy or agent

Tipo di dati

boolean

Alias
UMLS CUI [1]
C0280449
clinically active cns leukemia
Descrizione

clinically active cns leukemia

Tipo di dati

boolean

Alias
UMLS CUI [1]
C1332884
previously received a total cumulative dose of cytarabine > 6g/m2 in the last 6 months
Descrizione

previously received a total cumulative dose of cytarabine > 6g/m2 in the last 6 months

Tipo di dati

boolean

Alias
UMLS CUI [1,1]
C0010711
UMLS CUI [1,2]
C2986497
previously received > 1 induction regimen (defined as 1 or 2 cycles of a drug or a drug combination administered as remission induction therapy)
Descrizione

previously received > 1 induction regimen (defined as 1 or 2 cycles of a drug or a drug combination administered as remission induction therapy)

Tipo di dati

boolean

Alias
UMLS CUI [1]
C3179010
Ritorna all'inizio della pagina

Similar models

Eligibility Acute Myeloid Leukemia NCT01034410

1 moduli
Name
genere
Description | Question | Decode (Coded Value)
Tipo di dati
Alias
Item Group
C1512693 (UMLS CUI)
AML
Item
diagnosis of aml as defined by the world health organization (who) classification (vardiman 2009)
boolean
C0023467 (UMLS CUI [1])
AML refractory
Item
primary refractory aml (defined as a failure to achieve a cr or cri after therapy with curative intent) or aml in first relapse
boolean
C0023467 (UMLS CUI [1,1])
C0205269 (UMLS CUI [1,2])
ECOG
Item
ecog performance status 0, 1 or 2
boolean
C1520224 (UMLS CUI [1])
age
Item
age > 18 and < 70 years
boolean
C0001779 (UMLS CUI [1])
blasts on baseline bone marrow
Item
for patients presenting with primary refractory aml, > 20% blasts on baseline bone marrow assessment
boolean
C0023467 (UMLS CUI [1,1])
C0205269 (UMLS CUI [1,2])
C1982687 (UMLS CUI [2])
relapsed aml
Item
for patients presenting with relapsed aml, > 5% blasts on baseline bone marrow assessment
boolean
C1982687 (UMLS CUI [1])
C0023467 (UMLS CUI [2,1])
C0277556 (UMLS CUI [2,2])
Item Group
C0680251 (UMLS CUI)
acute promyelocytic leukemia
Item
an initial diagnosis of acute promyelocytic leukemia (as defined by french-american-british criteria (bennett 1976))
boolean
C0023487 (UMLS CUI [1])
secondary aml
Item
secondary aml, defined as aml evolving from antecedent hematological disorder or prior exposure to leukemogenic therapy or agent
boolean
C0280449 (UMLS CUI [1])
cns leukemia
Item
clinically active cns leukemia
boolean
C1332884 (UMLS CUI [1])
cumulative dose cytarabine
Item
previously received a total cumulative dose of cytarabine > 6g/m2 in the last 6 months
boolean
C0010711 (UMLS CUI [1,1])
C2986497 (UMLS CUI [1,2])
induction regimen
Item
previously received > 1 induction regimen (defined as 1 or 2 cycles of a drug or a drug combination administered as remission induction therapy)
boolean
C3179010 (UMLS CUI [1])
Ritorna all'inizio della pagina 

Contatto

Si prega di utilizzare questo modulo per feedback, domande e suggerimenti per miglioramenti.

I campi contrassegnati da * sono obbligatori.

Aiuto

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial